anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: Evidence for necrotising otitis externa (NOE) diagnosis and management is limited, and outcome reporting is heterogeneous. International best practice guidelines were used to develop consensus diagnostic criteria and a core outcome set (COS).
METHODS: The study was pre-registered on the Core Outcome Measures in Effectiveness Trials (COMET) database. Systematic literature review identified candidate items. Patient-centred items were identified via a qualitative study. Items and their definitions were refined by multidisciplinary stakeholders in a two-round Delphi exercise and subsequent consensus meeting.
RESULTS: The final COS incorporates 36 items within 12 themes: Signs and symptoms; Pain; Advanced Disease Indicators; Complications; Survival; Antibiotic regimes and side effects; Patient comorbidities; Non-antibiotic treatments; Patient compliance; Duration and cessation of treatment; Relapse and readmission; Multidisciplinary team management.Consensus diagnostic criteria include 12 items within 6 themes: Signs and symptoms (oedema, otorrhoea, granulation); Pain (otalgia, nocturnal otalgia); Investigations (microbiology [does not have to be positive], histology [malignancy excluded], positive CT and MRI); Persistent symptoms despite local and/or systemic treatment for at least two weeks; At least one risk factor for impaired immune response; Indicators of advanced disease (not obligatory but mut be reported when present at diagnosis). Stakeholders were unanimous that there is no role for secondary, graded, or optional diagnostic items. The consensus meeting identified themes for future research.
CONCLUSION: The adoption of consensus-defined diagnostic criteria and COS facilitates standardised research reporting and robust data synthesis. Inclusion of patient and professional perspectives ensures best practice stakeholder engagement.
FIELD: agriculture; livestock farming. SUBSTANCE: method involves application of different doses of diludine to control different stresses. The animals receive the drug with feed for 5-7 days prior to and after stress. The doses range from 12 mg/kg in weighing, veterinary treatment and changing feeding pattern in the first period of raising to 18 mg/kg in forming groups of animals, caudotomy and driving from the building for raising in the first period to another animal building for raising in the second period respectively. The dose is 18 mg/kg for 5-7 days before stress in transporting for slaughter. EFFECT: higher efficacy of stress prevention. 2 cl, 10 tbl
Gossypol, a naturally occurring compound found in cottonseed meal, shows promising therapeutic potential for human diseases. However, within the aquaculture industry, it is considered an antinutritional factor. The incorporation of cottonseed meal into fish feed introduces gossypol, which induces intracellular stresses and hinders overall health of farmed fish. The aim of this study is to determine the role of General control nonderepressible 2 (gcn2), a sensor for intracellular stresses in gossypol-induced stress responses in fish. In the present study, we established two gcn2 knockout zebrafish lines. A feeding trial was conducted to assess the growth-inhibitory effect of gossypol in both wild type and gcn2 knockout zebrafish. The results showed that in the absence of gcn2, zebrafish exhibited increased oxidative stress and apoptosis when exposed to gossypol, resulting in higher mortality rates. In feeding trial, dietary gossypol intensified liver inflammation in gcn2-/- zebrafish, diminishing their growth and feed conversion. Remarkably, administering the antioxidant N-acetylcysteine (NAC) was effective in reversing the gossypol induced oxidative stress and apoptosis, thereby increasing the gossypol tolerance of gcn2-/- zebrafish. Exposure to gossypol induces more severe mitochondrial stress in gcn2-/- zebrafish, thereby inducing metabolic disorders. These results reveal that gcn2 plays a protective role in reducing gossypol-induced oxidative stress and apoptosis, attenuating inflammation responses, and enhancing the survivability of zebrafish in gossypol-challenged conditions. Therefore, maintaining appropriate activation of Gcn2 may be beneficial for fish fed diets containing gossypol.
We expect 69 sites with 571 providers seeing 135,517 patients/year, corresponding to 95 providers/wave and 59 patients/provider/quarter. Patient data is retrospective and informs the primary outcome of provider adenoma detection rate. There is not a direct intervention for patients.
Patients with ureteral stones are often managed with a spontaneous trial of passage. While cost effective, the current literature has not examined the effects of a trial of passage on patients' work productivity. In this study, we aim to characterize work absence and productivity losses in a cohort of patients undergoing a trial of passage for ureteral stones. Actively employed patients aged 18 to 64 and discharged from Duke emergency departments without surgical intervention for ureteral stones ≤ 10 mm were contacted by phone four weeks after their presentation. Participants completed the Institute for Medical Technology Assessment Productivity Cost Questionnaire which assesses three domains: absenteeism - missed work; presenteeism -productivity when returning to work; and unpaid work - assistance with household work. Linear regression associated demographic and stone factors with productivity losses.109 patients completed the survey. In total, 67% of patients missed work, 46% had decreased productivity when returning to work, and 55% required assistance with unpaid work. 59% of patients with stones ≤ 5 mm missed work versus 84% with stones > 5 mm (p = 0.009). African American race (coefficient 23.68, 95% confidence interval 2.24-45.11, p = 0.031), first-time stone formers (coefficient 20.28, 95% confidence interval 2.50-38.07, p = 0.026), and patients with stones > 5 mm (coefficient 25.34, 95% CI 5.25-45.44, p = 0.014) were associated with increased productivity losses. The majority of patients miss work while undergoing a trial of passage and many have decreased productivity when returning to work. This information may help counsel patients in emergency departments, especially first-time stone formers, and prevent return visits.
A base for the preparation of ointments, skin creams or liniments comprises, either wholly or partially, an organic electroneutral salt which may be employed as a dispersion in water and is obtained by reaction of an anionic surface active compound containing at least one lipophilic residue having at least six carbon atoms with an equimolar quantity of a cationic surface active compound containing at least one aliphatic, cycloaliphatic or aliphatic aromatic residue having at least six carbon atoms, e.g. hydrocarbon residues having 16-22 carbon atoms which may contain hetero atoms, e.g. oxygen, sulphur, nitrogen, or hetero atom groups, e.g. ester, carbonamide, sulphonamide groups, or substituents, e.g. hydroxyl, mercapto, amino groups.  Suitable cation active compounds are onium compounds, e.g. ammonium, sulphonium and phosphonium compounds, and anion active compounds are water soluble salts of fatty acids having at least six carbon p  atoms or compounds containing inorganic acid groups; examples of both cation and anien active compounds are given. Examples of medicinal and disinfecting agents which may be incorporated in the preparation are included in the description.
The recommended starting dose of PRESTALIA is 3.5/2.5 mg once daily.

Adjust dosage according to blood pressure goals. In general, wait 7 to 14 days between titration steps. The maximum recommended dose is 14/10 mg once daily [see Clinical Pharmacology (12.3)].

PRESTALIA may be used as initial therapy if a patient is likely to need multiple drugs to achieve blood pressure goals. Consider use in patients unable to achieve adequate antihypertensive effect with amlodipine monotherapy because of dose-limiting peripheral edema caused by amlodipine [see Adverse Reactions (6)].

Administered as monotherapy, perindopril erbumine is an effective treatment for hypertension in once-daily doses ranging from 4 mg to 16 mg daily. Amlodipine is effective in once-daily doses of 5 mg and 10 mg. Adverse reactions related to perindopril are generally uncommon and independent of dose, while those related to amlodipine are a mixture of dose-dependent phenomena (primarily peripheral edema) and dose-independent phenomena, the former much more common than the latter [see Adverse Reactions (6)].
A preparation for the treatment of : Hair Loss and some skin diseases such as Seborreic dermatitis. The composition of the invention is designed to effectively stop hair  loss  (Alopecia).  The above  composition  is  further designed to help in the growth of hair, stimulating it, and has presents a multiple therapeutic action, described as follow : 1. Capillary nutrient, helps in hair stimulation and growth. 2. Reduces the inflammation of the underlying skin :    Anti-inflammatory effect. 3. Slows down the rapid rate of cell division that is responsible for the observed skin thickining in some cases : Anti-inflammatory and keratolytic effect.          The compositon comprises five essential substances in the variable proportions indicated below and expressed in weight : 1. -  wild melon agrume oil. 2. -  pure olive oil. 3. -  garlic oil, and 4. -  copper sulfate. 5. -  ROMARINUS OFFICINALIS essential oil.          The five ( 5 ) ingredients represent the active elements of this product, a scalp and hair treating composition.
In response to the urgent requirement for rapid, precise, and cost-effective detection in intensive care units (ICUs) for ventilated patients, as well as the need to overcome the limitations of traditional detection methods, researchers have turned their attention towards advancing novel technologies. Among these, biosensors have emerged as a reliable platform for achieving accurate and early diagnoses. In this study, we explore the possibility of using Pyocyanin analysis for early detection of pathogens in ventilator-associated pneumonia (VAP) and lower respiratory tract infections in ventilated patients. To achieve this, we developed an electrochemical sensor utilizing a graphene oxide-copper oxide-doped MgO (GO - Cu - Mgo) (GCM) catalyst for Pyocyanin detection. Pyocyanin is a virulence factor in the phenazine group that is produced by Pseudomonas aeruginosa strains, leading to infections such as pneumonia, urinary tract infections, and cystic fibrosis. We additionally investigated the use of DNA aptamers for detecting Pyocyanin as a biomarker of Pseudomonas aeruginosa, a common causative agent of VAP. The results of this study indicated that electrochemical detection of Pyocyanin using a GCM catalyst shows promising potential for various applications, including clinical diagnostics and drug discovery.
The donor area will be anesthetized with injected local anesthesia, harvested with the ART device, and bandaged with an occlusive dressing. The skin harvested will be placed on the recipient wound area. The area will be bandaged will a non-stick silicone dressing (covered by appropriate primary and secondary dressings) and left intact for 1-7 days.
NEW MATERIAL:The compound of formula 1 (R1 and R2 are H or lower alkyl; n is 0-2). EXAMPLE:3-Amino-5-ethoxycarbonylmethyl-2,3-dihydro-1,5-benzothiazepin-4( 5H )- one. USE:Remedy for hypertension and circulatory diseases. It has angiotensinase-inhibiting and hypotensive activities. PREPARATION:The compound of formula 1 can be prepared by (1) reacting the compound of formula 2 with the compound of formula 3 (X is Br, Cl or I) in the presence of a proper dechlorination agent such as sodium, sodium hydride, potassium hydride, etc. at a temperature between room temperature and the boiling point of the reaction mixture for 0.5-3hr to obtain the compound of formula 4 (R3 is lower alkyl), (2) optionally converting the compound of formula 4 to the compound of formula 5 by hydrolysis, etc., and (3) reacting the compound of formula 4 or the compound of formula 5 with the compound of formula 6 in the presence of a proper reducing agent.
In individuals without chronic kidney disease (CKD), potassium (K) lowers blood pressure (BP) and may help prevent cardiovascular disease (CVD) and stroke. In animal models, K prevented kidney injury and decreased kidney inflammation. CKD patients may especially benefit from higher K intake, due to their high prevalence of hypertension, CVD, and stroke, and the possibility that K may retard CKD progression. Despite these potential benefits, there is great uncertainty about the optimal K intake in CKD patients. K is often restricted in these patients due to concerns about elevating serum K. However, renal K excretion does not appear to be substantially impaired until the glomerular filtration rate (GFR) is severely decreased (\< 10-20 mL/min/1.73 m2). In this randomized feeding study with a two-period crossover design, the benefits and safety of 4 weeks of 100 mmol versus 40 mmol K/day in 26 non-diabetic adults with stage 3 CKD (estimated GFR 30-59 mL/min/1.73 m2) will be evaluated. After a one-week run-in period, all participants will be randomized to receive either a diet containing either 40 mmol K/day or 100 mmol K/day (within the current K/DOQI recommendations for K intake for stage 3 CKD) during period 1 (they will receive the other during period 2). The primary outcome variable is 24-hour ambulatory systolic BP. Secondary outcomes are other measures of peripheral BP, central BP, inflammatory markers, and serum K. We hope that this study will lead to a larger trial with sufficient power to examine the effects of increased K intake on clinical outcomes such as CKD progression. The ultimate goal of this effort is to develop the scientific basis for guidelines on K intake in CKD.
Disclosed is a physiologic monitoring system comprising a central hub in communication with a management portal for communicating physiologic measurements taken from a plurality of peripheral devices on a patient. At least one non-invasive peripheral device may measure physiologic data from a patient and be in communication with said central hub. A system including an invasive peripheral device may be associated with said patient and be in communication with said central hub. The central hub may be scalable to collect and communicate measurements from the non-invasive peripheral device and the invasive peripheral device. The at least one non-invasive peripheral device may include a blood pressure cuff, an oxygen sensor, a weight scale, and an ECG monitor. The invasive peripheral device may include a wireless sensor reader that may be adapted to measure physiologic data from a sensor implant placed within the cardiovascular system of said patient.
BACKGROUND: Locally advanced rectal cancer is typically treated using a combination of neoadjuvant chemoradiotherapy and total mesorectal resection. While achieving pathological complete response following neoadjuvant chemoradiotherapy has been recognized as a positive prognostic factor in oncology, the necessity of adjuvant chemotherapy for locally advanced rectal cancer patients with pathological complete response after surgery remains uncertain. The objective of this meta-analysis was to examine the impact of adjuvant chemotherapy on the oncological outcomes of rectal cancer patients who attain pathological complete response after neoadjuvant chemoradiotherapy.
METHODS: This meta-analysis followed the guidelines outlined in the preferred reporting items for systematic review and meta-analysis (PRISMA). The Web of Science, PubMed, and Cochrane Library databases were systematically searched to identify relevant literature.
RESULTS: A total of 34 retrospective studies, including 9 studies from the NCBD database, involving 31,558 patients with pathological complete response rectal cancer, were included in the meta-analysis. The included studies were published between 2008 and 2023. The pooled analysis demonstrated that adjuvant chemotherapy significantly improved overall survival (HR = 0.803, 95% CI 0.678-0.952, P = 0.011), and no heterogeneity was observed (I2 = 0%). Locally advanced rectal cancer patients with pathological complete response who underwent adjuvant chemotherapy exhibited a higher 5-year overall survival rate compared to those who did not receive adjuvant chemotherapy (OR = 1.605, 95% CI 1.183-2.177, P = 0.002). However, the analysis also revealed that postoperative ACT did not lead to improvements in disease-free survival and recurrence-free survival within the same patient population. Subgroup analysis indicated that pathological complete response patients with clinical stage T3/T4, lymph node positivity, and younger than 70 years of age may benefit from adjuvant chemotherapy in terms of overall survival.
CONCLUSIONS: The findings of this meta-analysis suggest that adjuvant chemotherapy has a beneficial effect on improving overall survival among rectal cancer patients with pathological complete response. However, no such association was observed in terms of disease-free survival and recurrence-free survival.
The invention discloses a Chinese medicinal preparation for treating facial neural paralysis. The preparation comprises fine powder of the following raw material medicaments in part by weight: 30 parts of scorpion, 10 parts of centipede, 20 parts of larva of silkworm with botrytis, 15 parts of cicada slough, 10 parts of nutgrass galingale rhizome and 10 parts of cinnabar. The Chinese medicinal preparation is taken when mixed with yellow wine. The selected medicaments have the effects of calming endogenous wind and relieving convulsion, activating meridians and relieving pain, and clearing away heat and toxic materials. The body immunity performance can be improved by oral administration, and the Chinese medicinal preparation has excellent curative effect for the facial neural paralysis caused by various reasons. Due to the application of the Chinese medicinal preparation, 272 patients are treated, and are healed within 1 to 5 days. Clinical application proves that the Chinese medicinal preparation has the advantages of quick response, remarkable treatment effect, high tolerance, low cost and no toxic or side effect.
FIELD: medicine. ^ SUBSTANCE: invention refers to medicine and aims at treatment of psoriatic skin areas, scalp or nails. It involves oral introduction 3 times a day of a composition containing about 400 mg of bosvellic acid and about 100 mkg of selenium. The acid is chosen from the group including beta-bosvellic acid, acetyl-beta-bosvellic acid, 11-keto-beta-bosvellic acid, acetyl-11-keto-beta-bosvellic acid. It is combined with local application of the composition containing about 400 mg of the specified acid. ^ EFFECT: offered method provides effective treatment without undesired by-effects that is ensured by developed introduction pattern of compositions based on bosvellic acid and selenium. ^ 4 cl, 2 tbl, 2 ex, 4 dwg
The subject is treat with placebo drug, 5 mg once daily, however it can be reduced to once every second day, or increased to as much as as 10 mg daily, depending on measured potassium levels. This is combined with the dose of mineralcorticoid receptor antagonist (spironolacton or eplerenon) 25 mg or 50 mg depending on what dose they could tolerate.
Medicaments contg. pharmaceutical quality activated charcoal mixed with a substance to give delayed release of the charcoal, are new. The substance which causes delayed release is e.g. a fat or hydrocarbon such as vaseline oil with an emulsifier or an emulsifier or an anti-foaming agent such as dimethicane with or without an emulsifier. They are used for treatment of intestinal disorders such as aerogasria, gastropathy, diarrhoea, colitis and entero-colitis. The charcoal remains active until it reaches the intestinal tract, and it is not unpleasant to take. Typically, the medicaments contain a fat or hydrocarbon to effect delayed release. In an example a compsn. contained 100 kg active charcoal, 20 kg vaseline oil, and 5 kg polyoxyethylene oleic glycerides. This was made into tablets weighing 100-300 mg.
Primary Objectives (Phase I Portion): 1). To determine the safety and tolerability of eltrombopag in elderly subjects with AML 2). To determine the maximally tolerated initial starting dose of eltrombopag for elderly subjects with AML Primary Objectives (Phase II portion): 1). To better define the safety and tolerability of eltrombopag in elderly patients with AML at the maximally tolerated starting dose Page 9 of 18 determined in Phase I portion of study. 2). To determine the incidence of peripheral platelet count improvement (using baseline and response parameters as defined below) for subjects with disease related thrombocytopenia. Secondary Objectives (Phase I and II): 1). To preliminarily determine the efficacy (using AML response criteria as defined below) of eltrombopag in elderly subjects with AML.

2). To perform ex-vivo analyses using subject AML samples and stock eltrombopag to 1) assess leukemic proliferative capacity and 2) investigate potential eltrombopag induced cytoxic mechanisms for leukemic cell death. 3). To perform pharmacodynamic assessments of drug activity in leukemic cells using subject samples collected at various time points before and during drug exposure. 4). To preliminarily correlate pharmacodynamic findings with clinical response.
Motesanib placebo-matching tablets, orally, once daily and paclitaxel 200 mg/m\^2, intravenous, once on Day 1 and carboplatin at a dose to achieve a target AUC of 6.0 mg/mL x minute, once on Day 1 of a 3 week Cycle for up to 6 Cycles. After 6 Cycles, motesanib placebo-matching, tablets, orally, once daily alone until disease progression, drug intolerability, study withdrawal or death for up to 36 months.
This study will be divided into two stages. In the first stage the investigators will assess the transplant kidney with ultrasound after contrast injection (Sonazoid) to determine if contrast in the kidney is detectable by ultrasound and to determine if the amount of perfusion can be quantified directly or qualitatively. The investigators aim to have one to two subjects in this stage. If perfusion of the kidney can be assessed, then the investigators will move to stage two of the study.

In stage 2, the investigators will look to determine the ability of the contrast enhanced ultrasonography method to detect renal transplant rejection using Sonazoid. For this stage the investigators will recruit subjects with biopsy confirmed renal transplant rejection. Once subjects are consented, they will undergo contrast enhanced ultrasonography with Sonazoid and have images taken. These images will be compared to images of renal transplant patients that have displayed no rejection or clinical issues. These clinically normal subjects will have previously consented to a medical record review so that the investigators may use their images.
Patients will be randomized to receive either 20 mg/day of fluoxetine (one pill) or placebo (one pill), to be started one week prior to the scheduled hospital admission date. The dose will be increased to two pills per day on day 1 of hospitalization. On the day of discharge from the hospital, the study medication will be reduced to 1 pill per day and the patient will be instructed to stop the medication one week following discharge.